Navigation Links
Perrigo Company Announces Appointment Of New Board Of Directors Member
Date:11/6/2012

ALLEGAN, Mich., Nov. 6, 2012 /PRNewswire/ -- The Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors has appointed Jacqualyn A. Fouse, Ph.D. as a new director of the Company.

(Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO )

Perrigo's Chairman, President and CEO Joseph C. Papa stated, "Jackie's outstanding background has served her well in leadership roles at several pharmaceutical and healthcare companies. Her broad business and strategic acumen will allow her to make excellent contributions to our Board. We are pleased to welcome Jackie to the Perrigo Board of Directors."

Jacqualyn A. Fouse, 51, has served as Executive Vice President and Chief Financial Officer of Celgene Corporation, a leading global biopharmaceutical company, since September of 2010. From July 2007 until September 2010, she previously served as Chief Financial Officer for Bunge Ltd., a leading global agribusiness and food company. From 2002 to July 2007, Ms. Fouse served as Senior Vice President, Chief Financial Officer and Corporate Strategy, at Alcon Laboratories, a leading eye care company. Prior to Alcon Laboratories, Ms. Fouse was Chief Financial Officer of Swissair Group in Switzerland, 2001 – 2002, and she was Group Treasurer of Nestle S.A. in Switzerland from 1999 to 2001. Ms. Fouse held various senior level financial positions in both the U.S. and Switzerland with both Alcon and Nestle form 1986 to 1999. She also held positions with LTV Aerospace and Defense and Celanese Chemical Company from 1983 to 1986. Ms. Fouse currently serves on the Board of Dick's Sporting Goods, a leading U.S. retailer of sporting goods and athletic apparel.     

From its beginnings as a packager of generic home remedies in 1887, Perrigo Company, based in Allegan, Michigan, has grown to become a leading global provider of quality, affordable healthcare products. The Company develops, manufactures and distributes over-the-counter ("OTC") and generic prescription ("Rx") pharmaceuticals, nutritional products and active pharmaceutical ingredients ("API") and is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. Perrigo's mission is to offer uncompromised "quality, affordable healthcare products", and it does so across a wide variety of product categories primarily in the United States, United Kingdom, Mexico, Israel and Australia, as well as certain other markets throughout the world, including Canada, China and Latin America. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2012, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Company To Acquire Assets Of Sergeants Pet Care Products, Inc., For $285 Million
2. Perrigo Company To Present At The Morgan Stanley Global Healthcare Conference
3. Perrigo Company Announces Quarterly Dividend
4. Perrigo Receives FDA Approval And Commences Launch Of Clobetasol Propionate Shampoo, 0.05%
5. Perrigo Company To Present At The William Blair Growth Stock Conference
6. Perrigo Announces FDA Final Approval Of Tris Pharmas Dextromethorphan Polistirex Extended-Release Oral Suspension
7. Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream
8. Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules
9. Perrigo Company to Present at the Bank of America Merrill Lynch 2012 Healthcare Conference
10. Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance
11. Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , January 19, 2017 According to ... for cryotherapy is set to witness a CAGR of 6.5% during ... America will continue to be the leading market for ... ... Suppliers are emphasizing on ensuring affordable and adequate supply of gas ...
(Date:1/19/2017)... Jan. 19, 2017 ViewRay, Inc. (Nasdaq: VRAY) announced ... institution supporting research in Germany , ... treatments at the University Clinic Heidelberg as part of ... MRIdian Linac program will be headed by Medical Director ... radiation oncology at the German Cancer Research Center (DKFZ), ...
(Date:1/19/2017)... BEACH, Florida , January 19, 2017 /PRNewswire/ ... incoming Trump administration appears serious about reducing the ... advancements and innovation in the medical drug industry, ... forge ahead with new clinical trials and development ... Pharma companies forging ahead with recent developments include:  ...
Breaking Medicine Technology:
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... Doctor ... announced it attended the January ECRM trade show to continue the marketing and distribution ... vitamin C supplement, known for providing 400 percent better absorption than traditional vitamin C ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Michael and ... Dana Farber Cancer Institute. For Betsy, the clinical trial has been life-saving as ... has not worsened. , Betsy Brauser was diagnosed with ovarian cancer in 2009. ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following ... Chocolate Biscuit” is the creation of published author, Marlyn Ivey, born in Lynn Haven, Florida ... went to school and at 19 years of age, he joined the Navy and got ...
(Date:1/20/2017)... ... ... is God’s Lighthouse”: a moving and colorful collection of prayers that reminds readers ... author, Gene Gaapf, a retired truck driver, and a long-time writer, whose published works ... school and have many different titles,” Gaapf mentions about his different works. “I am ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Next week after ... be repealed by Congressional political games that circumvent health needs of over 30 million. ... capture the human anxieties and needs government public servants were suppose to prioritize. Interviews ...
Breaking Medicine News(10 mins):